Terming the US as a high growth market for the company, the Mumbai-based firm said it aims to grow at around 25 percent in the world's largest drug market.
Looking to bolster its overseas presence, drug major Lupin is scouting for acquisition
opportunities in the US market, especially in inhalers and injectables segments.
"We continue to evaluate opportunities and going forward acquisitions in the US would have to satisfy our multiple aspirations of creating a meaningful speciality business,
bolstering our existing brands business and acquiring technological capabilities that we would like to work on," Lupin CFO S Ramesh told PTI.
The company continues to be on the lookout for meaningful targets, be it brands or technology companies, in inhalation, complex injectables and skin diseases segments, he added.
Terming the US as a high growth market for the company, the Mumbai-based firm said it aims to grow at around 25 percent in the world's largest drug market.
"For Lupin, the US is a high growth market and the major contributor to the company's overall revenues and profitability... We don't give guidances but if the past is
prescriptive of the future we would aim to maintain our current growth momentum for the US market between 20-25 percent," Ramesh said.
The company remains the 5th largest and fastest growing top five generic players in the US for the third year now, he added.
As per IMS Health data, Lupin currently has close to 5.4 percent market share of the overall US generics market.
The US formulation sales contributed 44 percent to the company's overall consolidated revenue for FY14.
US revenues grew by 16 per cent to USD 803 million during FY14 out of which the generic business contributed USD 723 million.
As of June 30, 2014, the company's cumulative abbreviated new drug application (ANDA) filing with the US Food and Drug Administration (USFDA) stood at 200 with the company having received 103 approvals.
"Currently 97 ANDA's are pending for approval and launch; addressing an opportunity of over USD 80 billion... 31 filings out of which are first-to-file (FTF) opportunities," Ramesh
said.
Shares of Lupin were trading 1.52 per cent down at Rs 1,364 apiece on the BSE.
Lupin stock price
On October 21, 2014, Lupin closed at Rs 1367.85, down Rs 17.15, or 1.24 percent. The 52-week high of the share was Rs 1442.30 and the 52-week low was Rs 841.10.
The company's trailing 12-month (TTM) EPS was at Rs 65.28 per share as per the quarter ended March 2014. The stock's price-to-earnings (P/E) ratio was 20.95. The latest book value of the company is Rs 155.46 per share. At current value, the price-to-book value of the company is 8.80.
Anda sedang membaca artikel tentang
Lupin scouts for acquisitions in US
Dengan url
http://kebugaranhidup.blogspot.com/2014/10/lupin-scouts-for-acquisitions-in-us.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Lupin scouts for acquisitions in US
namun jangan lupa untuk meletakkan link
Lupin scouts for acquisitions in US
sebagai sumbernya
0 komentar:
Posting Komentar